Le Lézard
Classified in: Health, Science and technology
Subject: TRI

Research Solutions Unveils AI Platform for Automated Clinical Trial Landscape Reports


Powerful AI, combined with comprehensive data, simplifies the discovery and synthesis of clinical trial information to accelerate innovation in the medical field

HENDERSON, Nev., April 15, 2024 /PRNewswire/ -- Research Solutions (NASDAQ: RSSS), a trusted partner providing cloud-based workflow solutions to accelerate research for R&D-driven organizations, today launches their new Clinical Trial Landscape software solution, making clinical trial information more accessible, insightful, and actionable. Clinical trials are essential research studies that assess the efficacy and safety of medical interventions, informing regulatory decisions, guiding healthcare practices, and advancing medical knowledge and patient care.

This addition to Research Solutions' product family uses AI to transform how medical science liaisons, medical affairs specialists, and clinical development teams explore, review, and synthesize multiple clinical trials and relevant data to map the overall landscape quickly.

Designed with precision, this new tool addresses the critical need for comprehensive, bias-free access to global clinical trial information and a streamlined process for identifying and summarizing available insights. Offering features such as adverse event filtering, detailed analytics, and guided search and refinement, the Clinical Trial Landscape solution ensures users can efficiently identify the most experienced Principal Investigators (PIs) and relevant publications for their specific research areas.

Key benefits include:

"With our advanced AI and comprehensive data, we're able to help teams and individuals navigate the vast landscape of clinical research, efficiently and effectively," said Eléonore Dixon-Roche, Product Manager at Research Solutions.

The launch of the Clinical Trial Landscape solution represents another significant step forward in Research Solutions' commitment to fostering progress in the scientific community. It is expected to solidify further their position as a leader in scientific data integration, as well as drive growth by attracting new users and strengthening relationships with existing customers.

With this software solution launch, their acquisitions of ResoluteAI and scite, and the recent introduction of their Technology Landscape solution, Research Solutions is building a robust ecosystem designed to fuel innovation and deliver strategic advantages to customers.

To learn more about the Clinical Trial Landscape, and to see firsthand how this solution advances innovations in the healthcare and medical sectors, join their upcoming webinar: https://bit.ly/3PE0ETB.

About Research Solutions

Research Solutions, Inc. (NASDAQ: RSSS) provides cloud-based technologies to streamline the process of accessing, managing, and creating intellectual property. Since its founding, the company has been a pioneer in developing solutions to serve researchers. Today, more than 70 percent of the top pharmaceutical companies, prestigious universities, and emerging businesses rely on our family of products, powered by AI and NLP technologies, to support the innovation process from end to end with the most comprehensive information and knowledge tools on the market. For more information and details, please visit www.researchsolutions.com.

Important Cautions Regarding Forward-Looking Statements

Certain statements in this press release may contain "forward-looking statements" regarding future events and our future results. All statements other than statements of historical facts are statements that could be deemed to be forward-looking statements. These statements are based on current expectations, estimates, forecasts, and projections about the markets in which we operate and the beliefs and assumptions of our management. Words such as "expects," "anticipates," "targets," "goals," "projects", "intends," "plans," "believes," "seeks," "estimates," "endeavors," "strives," "may," or variations of such words, and similar expressions are intended to identify such forward-looking statements. Readers are cautioned that these forward-looking statements are subject to a number of risks, uncertainties and assumptions that are difficult to predict, estimate or verify. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Such risks and uncertainties include those factors described in the Company's most recent annual report on Form 10-K, as such may be amended or supplemented by subsequent quarterly reports on Form 10-Q, or other reports filed with the Securities and Exchange Commission. Examples of forward-looking statements in this release include statements regarding additional customers, potential acquisitions and the Company's prospects for growth, profitability, and cash flow. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements. For more information, please refer to the Company's filings with the Securities and Exchange Commission.

For more information about Research Solutions, visit: www.researchsolutions.com | LinkedIn | Facebook | Twitter

SOURCE Research Solutions, Inc.

SOURCE Research Solutions, Inc.


These press releases may also interest you

at 10:02
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Instituto Mário Penna is live on the SOPHiA DDMtm Platform. Located in Belo Horizonte, Brazil, the Instituto Mário Penna...

at 10:01
Phenomix Sciences (Phenomix), a precision medicine biotechnology company that brings data intelligence to the treatment of obesity, announces the results of a groundbreaking independent study led by Mayo Clinic and presented at Digestive Disease Week...

at 10:00
Up to 18% of patients undergoing ACL reconstruction experience graft failure and require revision surgery, which is known to increase the risk of developing post-traumatic osteoarthritis (PTOA). A new trial led by the Center for Regenerative Medicine...

at 10:00
Latham & Watkins LLP1 is pleased to announce that Jennifer Bragg and William (Bill) McConagha have joined the firm's Healthcare & Life Sciences Practice in the Washington, D.C. office. Bragg and McConagha bring a powerful combination of deep...

at 10:00
SightMD, a leading multi-specialty ophthalmology practice in...

at 10:00
A trailblazing new concept combining a mind, body, and soul approach to personal growth and fitness is coming to an area near you! Todd Durkin, internationally recognized mindset coach, and fitness trainer behind some of the...



News published on and distributed by: